Prot #BDTX‐1535‐101: A Phase 1 Study to Assess BDTX‐1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non‐Small Cell Lung Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date7/21/237/21/26

Funding

  • Novella Clinical, LLC (Prot #BDTX-1535-101 // Prot #BDTX-1535-101)
  • Black Diamond Therapeutics, Inc. (Prot #BDTX-1535-101 // Prot #BDTX-1535-101)